Miami Cancer Institute Hematologic Oncology Grand Rounds Evaluation - February 25, 2020

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	NA
The skills learned in this CME course enhanced my professional competence.	The skills learned in this CME course enhanced my professional competence. - 5	The skills learned in this CME course enhanced my professional competence. - 4	The skills learned in this CME course enhanced my professional competence. - 3	The skills learned in this CME course enhanced my professional competence. - 2	The skills learned in this CME course enhanced my professional competence. - 1	The skills learned in this CME course enhanced my professional competence. - NA
The skills learned in this CME course will be applied in the treatment of my patients	The skills learned in this CME course will be applied in the treatment of my patients - 5	The skills learned in this CME course will be applied in the treatment of my patients - 4	The skills learned in this CME course will be applied in the treatment of my patients - 3	The skills learned in this CME course will be applied in the treatment of my patients - 2	The skills learned in this CME course will be applied in the treatment of my patients - 1	The skills learned in this CME course will be applied in the treatment of my patients - NA

As a result of attending this conference, to what extent do you agree that you will be better able to: (rate the objectives) *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	N/A
Identify available prognostic models and their limitations.	Identify available prognostic models and their limitations. - 5	Identify available prognostic models and their limitations. - 4	Identify available prognostic models and their limitations. - 3	Identify available prognostic models and their limitations. - 2	Identify available prognostic models and their limitations. - 1	Identify available prognostic models and their limitations. - N/A
Define the role and risks of obintuzumab-based therapy for FL in first-line and relapsed settings.	Define the role and risks of obintuzumab-based therapy for FL in first-line and relapsed settings. - 5	Define the role and risks of obintuzumab-based therapy for FL in first-line and relapsed settings. - 4	Define the role and risks of obintuzumab-based therapy for FL in first-line and relapsed settings. - 3	Define the role and risks of obintuzumab-based therapy for FL in first-line and relapsed settings. - 2	Define the role and risks of obintuzumab-based therapy for FL in first-line and relapsed settings. - 1	Define the role and risks of obintuzumab-based therapy for FL in first-line and relapsed settings. - N/A
Summarize the failure of PFS24 failure as prognostic model and implications for therapeutic decision-making.	Summarize the failure of PFS24 failure as prognostic model and implications for therapeutic decision-making. - 5	Summarize the failure of PFS24 failure as prognostic model and implications for therapeutic decision-making. - 4	Summarize the failure of PFS24 failure as prognostic model and implications for therapeutic decision-making. - 3	Summarize the failure of PFS24 failure as prognostic model and implications for therapeutic decision-making. - 2	Summarize the failure of PFS24 failure as prognostic model and implications for therapeutic decision-making. - 1	Summarize the failure of PFS24 failure as prognostic model and implications for therapeutic decision-making. - N/A
Identify targeted agents including lenalidomide and copanlisib in the treatment of FL.	Identify targeted agents including lenalidomide and copanlisib in the treatment of FL. - 5	Identify targeted agents including lenalidomide and copanlisib in the treatment of FL. - 4	Identify targeted agents including lenalidomide and copanlisib in the treatment of FL. - 3	Identify targeted agents including lenalidomide and copanlisib in the treatment of FL. - 2	Identify targeted agents including lenalidomide and copanlisib in the treatment of FL. - 1	Identify targeted agents including lenalidomide and copanlisib in the treatment of FL. - N/A

How satisfied or dissatisfied were you with the following conference content? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied

	5	4	3	2	1
Lecture materials.	Lecture materials. - 5	Lecture materials. - 4	Lecture materials. - 3	Lecture materials. - 2	Lecture materials. - 1
Speaker's effectiveness in addressing the learning objectives.	Speaker's effectiveness in addressing the learning objectives. - 5	Speaker's effectiveness in addressing the learning objectives. - 4	Speaker's effectiveness in addressing the learning objectives. - 3	Speaker's effectiveness in addressing the learning objectives. - 2	Speaker's effectiveness in addressing the learning objectives. - 1

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

What, if any, new skills/strategies will you apply in your clinical practice? *

If you do not plan to implement any new skills/strategies in your clinical practice, what is keeping you from doing so? *

Please provide any additional comments or suggestions.

Name

You are here

Miami Cancer Institute Hematologic Oncology Grand Rounds Evaluation - February 25, 2020